Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Obesity with MAFLD
NCT06501326Phase 4Unknown
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide in obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Affiliated Hospital of Nantong University. Status: unknown.
02
Drugs
03
Conditions
obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06501326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501326.